Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC — Stella

Recruiting

Back to Non-Small Cell Lung Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Icahn School of Medicine at Mount Sinai, New York, New York

Key details

Phase

Early testing / Safety & dosing

Sponsor

Icahn School of Medicine at Mount Sinai

Enrollment target

~21 participants

Started

March 2024

Primary completion

April 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov